Drugs / Anumigilimab
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT05653713 | Dec 2022 → Jul 2023 | — | CSL Behring | Completed | No outcome recorded |
| Phase 1 | NCT04570267 | Oct 2020 → Nov 2021 | — | CSL Behring | Completed | No outcome recorded |
| Phase 1 | NCT03972280 | Jul 2019 → Oct 2022 | hidradenitis suppurativa, palmoplantar pustulosis | CSL Behring | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07224360 | Feb 2026 → Jun 2028 expected | sickle cell disease | CSL Behring | Recruiting | No outcome recorded |
| Phase 2 | NCT04519424 | Sep 2020 → Apr 2021 | COVID-19 | CSL Behring | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anumigilimab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07224360 ↗ |
| Known as | CSL324 | “Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)” NCT07224360 ↗ |
| Action | Inhibit | “Granulocyte colony stimulating factor receptor antagonist” CHEMBL4650461 ↗ |
| Modality | Monoclonal antibody | “recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody” NCT03972280 ↗ |
| Route | Intravenous | “suitable for intravenous infusion” NCT03972280 ↗ |
| Target | CSF3R | “Granulocyte colony stimulating factor receptor antagonist” CHEMBL4650461 ↗ |